Gelita AG

Disclosure context. GELITA files statutory accounts with the German Federal Gazette (Bundesanzeiger / Unternehmensregister); one aggregator notes 18 annual statements on file for GELITA AG [S3]. Consequently, nearly all five-year metrics are not publicly disclosed here. The few available data points are presented below; they are not audited consolidated figures unless noted.

Long-run revenue history

Sources: FY2004 [S20]; FY2005 [S16]; FY2011 [S15]; FY2018 [S10]; FY2019 [S13]. Employee figure for FY2004 from encyclopaedic profile [S11]; FY2005 from 2006 press [S16].

Data conflicts to note.

• FY2004 vs FY2005: A 2005 trade report states FY2004 turnover of EUR 454 million (down EUR 18 million year-on-year) and profit of EUR 35 million [S20]; a 2006 report gives FY2005 turnover of EUR 428 million [S16]. An encyclopaedic profile gives 2004 sales of USD 549.3 million [S11], broadly consistent with EUR 454 million at 2004 exchange rates.

• Latest revenue: the website states EUR 839 million "annual sales" without a year [S7]; RocketReach estimates USD 843.3 million for 2025 [S18]; Similarweb places revenue in a USD 500 million–1 billion band [S19]. A registry aggregator shows EUR 353.5 million revenue and a EUR 700 million balance-sheet total for the single entity GELITA AG (balance-sheet total stated for 2022) [S3][S4] — this is parent-company HGB data, not group revenue, and should not be compared with the group figures.

Revenue CAGR (derived from company-stated figures).

• FY2011 → FY2019: EUR 510 million → EUR 749 million ≈ 4.9% CAGR.

• FY2005 → FY2019: EUR 428 million → EUR 749 million ≈ 4.1% CAGR.

• FY2019 → "EUR 839 million" (year unstated): if the figure relates to FY2022, the implied CAGR would be ≈ 3.9%.

• Revenue per employee FY2019 ≈ EUR 0.30 million (749 / ~2,500).

• Profit data point: FY2004 annual profit EUR 35 million (≈7.7% net margin on EUR 454 million) [S20] — the only disclosed historical profit figure found.

Balance sheet

Disclosed financing. In June 2022 GELITA extended its existing EUR 100 million syndicated financing line by five years (with two one-year extension options), widened permitted acquisition baskets and amended a remaining financial covenant. Lenders: DZ Bank, Helaba, Deutsche Bank Luxembourg, LBBW, HSBC Trinkaus & Burkhardt and Volksbank Neckartal; counsel Heuking Kühn Lüer Wojtek [S12]. The facility size relative to ~EUR 750–840 million of revenue indicates a conservatively geared balance sheet, though drawn amounts are not disclosed.

Cash flow

The only disclosed capex figure is over EUR 56 million in 2017, with the majority allocated to capacity expansion for collagen peptides [S23]; the USD 22 million Sergeant Bluff project formed part of this programme [S14].

Commentary on trends, inflections and drivers

Revenue trajectory. GELITA's disclosed top line grew from roughly EUR 430–450 million in the mid-2000s to about EUR 750 million by 2018–19, a mid-single-digit compound rate. The step-up between 2005 and 2011 coincided with expansion in China (Liaoyuan, 2006) and strong 2011 growth of 16.5% despite a weak macro backdrop, which management at the time attributed to its strategic positioning [S15]. Revenue was flat between FY2018 (EUR 750 million) and FY2019 (EUR 749 million), a period in which gelatin pricing softened and African swine fever disrupted Chinese pork supply. The EUR 839 million figure on the website implies further growth in the early 2020s, very likely helped by the SelJel consolidation (from December 2020) and the post-pandemic inflationary pass-through of raw-material and energy costs.

Margin drivers (qualitative). Three variables dominate gelatin economics: (i) raw-material cost and availability (pig skin and bovine hide/bone pricing track slaughter volumes and competing uses such as rendering and leather); (ii) energy costs, given energy-intensive drying and evaporation — highly relevant to GELITA's four German plants after the 2022 European gas-price shock; and (iii) mix shift toward branded peptides. The company's reported investments in a gas-fired power station at Beaudesert and a new spray dryer at Minden [S27] were framed as decarbonisation projects but also address energy efficiency.

Inflection points. Likely inflections, none of which can be quantified from public data: 2022 (energy shock, price increases), 2023–24 (normalisation and leadership turnover), and 2025–26 (competitor consolidation via Nextida and PB Leiner capacity closures, which may tighten European supply and support pricing for remaining producers).

Management guidance

None published. The only forward commitments are the GHG targets (−50% by 2030; net zero by 2050) and the qualitative "GELITA 2030" ambition of above-market growth [S25][S27].

Consensus growth expectations

None (no analyst coverage). Market proxies suggest gelatin value growth of ~5.5–7% per year [S62][S30], with collagen peptides growing faster.

Bull case

1. Supply tightening in Europe — PB Leiner's Treforest and Vilvoorde closures [S42][S43] reduce competitor capacity in GELITA's home market, supporting volumes and pricing.

2. Mix shift to BCP® — A continuing pipeline (PeptENDURE® 2023, OPTIBAR® 2024, CONFIXX® 2025, CURADERM® 2026) and new clinical evidence support premium pricing in a market where value growth exceeds volume growth.

3. Geographic leverage — Liaoyuan's 11,000 t base and near-full SelJel ownership position GELITA in Asia and halal markets where demand growth is strongest.

Bear case

1. Structural scale gap — Nextida, with ~200,000 t capacity and Darling's raw-material integration, could pressure GELITA on cost and key-account pricing.

2. Governance risk — Three CEOs in 2024 and a reported family dispute could slow decision-making and capital allocation.

3. Opacity and balance-sheet uncertainty — Without disclosed financials, stakeholders cannot assess margins after the 2022 energy shock; the disclosed EUR 100 million facility suggests limited firepower for transformational M&A.

Catalysts and monitorables (next 12 months)

Analyst verdict

GELITA AG is a high-quality, under-disclosed industrial franchise at a strategic crossroads. For roughly 150 years it has converted meat-industry by-products into gelatin and, increasingly, into science-backed collagen peptides, building what it describes as a 23% global share and a portfolio of indication-specific brands that few competitors can match in clinical depth. The disclosed record — revenue rising from about EUR 430–450 million in the mid-2000s to EUR 749 million in 2019 and an unstated-year EUR 839 million thereafter — demonstrates durable mid-single-digit growth in a market whose value is growing considerably faster than its volume. That gap is GELITA's opportunity: the more the business shifts toward branded peptides and engineered pharma gelatins, the more it resembles a specialty-nutrition ingredients company rather than a commodity processor.

The risk is that the industry is consolidating around a larger, vertically integrated competitor. Darling's Gelnex purchase and the pending Nextida combination with PB Leiner produce a rival with roughly double GELITA's capacity and direct control over raw materials. GELITA's response so far has been incremental and sensible — deepening its halal position through SelJel, scaling Liaoyuan, launching new peptide brands, and entering bioscience — but its financial firepower and post-2024 governance stability remain unproven to outsiders.

On balance, GELITA's competitive position looks defensible but no longer dominant. Its near-term prospects are supported by competitor capacity exits in Europe and a strong innovation cadence; its medium-term outcome depends on whether the new CEO can turn the family's long-term orientation into decisive capital allocation — through targeted acquisitions, accelerated peptide capacity, and energy-cost reduction — before Nextida's integration benefits flow through. Stakeholders should treat the absence of published financials as a material diligence gap and prioritise retrieving GELITA's statutory filings from the German company register.